Electronic detection.
Solid-state technology.
Polymerase free.
A new way of sequencing the human genome.
NABsys aims to make whole-genome DNA sequencing fast, inexpensive, and accurate enough to be used in clinical care. Our approach builds on existing solid-state technologies to create a whole-genome sequencing technology that employs electronic detection, does not depend on a polymerase, and directly obtains DNA sequence information over hundreds of thousands of bases.
Electronic Detection
Electronic detection allows for high speed, high sensitivity single-molecule analysis. Our electronic approach allows for single-molecule detection with a signal-to-noise ratio that is an order of magnitude higher than the world’s most advanced optical sequencing technologies.
Solid-State Technology
By using all solid-state materials, NABsys is able to build on the incredible advances in the semiconductor industry that have taken place over the last half-century. By applying semiconductor fabrication technology to the bioanalytical arena, NABsys has created a dramatically new way of sequencing DNA.
Polymerase-Free
Other sequencing technologies depend on enzymes known as polymerases to aid their sequencing platforms. Dependence on polymerases leads to problems in the performance of these platforms. NABsys has completely eliminated polymerase from its sequencing technology.
Long-Range Sequence Information
Other DNA sequencing technologies are processive and accumulate error as they go. As a result, they are limited to obtaining information about DNA sequences in small bits known as “reads.” The shorter these “read lengths” the greater the difficulty created for the associated sequencing platform. Because the NABsys approach is not processive, our DNA sequencing technology has no read-length associated limitations.
NABsys is a life sciences company working at the intersection of physics, biology, and computer science to revolutionize medicine through clinical-grade whole-genome DNA sequencing. NABsys is one of five companies to receive a “$1000 Genome” award from the National Human Genome Research Institute of the National Institutes of Health.
05.04.2009
NABsys, Inc., Announces $4M Equity Round
A non-technical summary of the NABsys approach to DNA sequencing which highlights the benefits of our approach and potential applications.
A more detailed summary of the actual physical processes which we are employing to sequence DNA.